Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2022-01, Vol.139 (4), p.624-629
Hauptverfasser:	Garcia-Manero, Guillermo, Mufti, Ghulam J., Fenaux, Pierre, Buckstein, Rena, Santini, Valeria, Díez-Campelo, María, Finelli, Carlo, Ilhan, Osman, Sekeres, Mikkael A., Zeidan, Amer M., Ito, Rodrigo, Zhang, Jennie, Rampersad, Anita, Sinsimer, Daniel, Backstrom, Jay T., Platzbecker, Uwe, Komrokji, Rami S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Activin Receptors, Type II - therapeutic use Adult Aged Aged, 80 and over Blood Platelets - cytology Blood Platelets - drug effects Female Hematinics - therapeutic use Humans Immunoglobulin Fc Fragments - therapeutic use Letter to Blood Leukocyte Count Male Middle Aged Myelodysplastic Syndromes - drug therapy Neutrophils - cytology Neutrophils - drug effects Platelet Count Recombinant Fusion Proteins - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!